Luke Halpern, Assistant Editor

The new approach could optimize precision medicine and lead to better outcomes across a variety of disease states.

The FDA’s designation builds off positive results in a phase 1b/2a clinical trial, showing that the vaccine can effectively target the Tau protein.

Adherence and efficacy were both higher in patients with HIV who took twice-yearly lenacapavir compared to those on oral preexposure prophylaxis medication.

Emerging treatments, collaboration between health care providers, and new policy proposals have led to a positive outlook for the future of nonalcoholic steatohepatitis (NASH) and its treatment.

It is essential for clinicians to properly diagnose patients with suspected AVWS and provide them proper treatment, which could be intravenous immunoglobulin.

With new guidance coming for the 2024-2025 season, pharmacists must stay up to date with current vaccine recommendations.

Eculizumab-aagh does not have an interchangeable designation, though that could be updated in the future.

There were positive efficacy and safety results for tivozanib monotherapy consistent with previous analyses.

In a study of Swedish patients with mantle cell lymphoma, the participants faced a heightened risk of infection after their diagnosis and associated treatment for the disease.

The cause of the outage was deemed to be due to a defect found in a content update for Windows users.

A large portion of the population of patients in the United States with GERD have the non-erosive type of the disease.

A patient with severe and recurrent pemphigus vulgaris achieved lasting remission with a novel intravenous immunoglobulin preparation that had the added benefit of reducing treatment-related side effects.

Investigators compared the criteria for eligibility in the VICTORIA trial with guideline and label criterion, finding a wider than expected population with heart failure were eligible for vericiguat therapy.

Allison Burns discusses how pharmacists should prepare and educate themselves regarding OTC naloxone, and the steps that can be taken in stores and pharmacies to ensure OTC naloxone is visible and available.

Allison Burns, president and CEO of EMO Health, discusses the price point and stigma surrounding OTC naloxone in an interview with Pharmacy Times.

An analysis of interaction checkers and product summaries revealed large differences in the consistency and reliability of providing accurate information on potential drug-drug interactions.

In pediatric and adult patients, the top 3 surgical procedures accounted for the highest share of opioid prescriptions, indicating a need for better opioid prescription management and greater awareness of the possible opioid-related adverse events that can stem from prescriptions of the drug.

In a follow-up to the interim FTC report documenting the business practices of PBMs and the power they hold in the pharmaceutical industry, the Commission now seeks to sue the 3 largest PBMs in the country for driving up the price of insulin and other essential drugs.

Intravenous immunoglobulin was effective as an adjunctive treatment to anticoagulation in a patient with post-viral platelet-activating anti-PF4 disorder, indicating the need for accurate diagnosis and treatment selection.

The RECTIFIER framework was able to screen patients with heart failure more accurately and with a cheaper cost than traditional screening methods.

In a new report, the FTC says pharmacy benefit managers act as middlemen in the pharmaceutical industry, leading to the squeezing of independent pharmacies and increases in prices for patients.

Individuals with tattoos were found to have a greater risk of developing malignant lymphoma, with the risk being highest within 2 years of receiving a tattoo.

Following the previous FDA approval of faricimab-svoa to treat some of the leading causes of vision loss, the Administration has approved a single-dose prefilled syringe of the drug which could lead to safer and more efficient administration while easing patient burden.

By developing the Shizuoka score, which features a new predictive model using machine learning, patients with Kawasaki disease who are non-responders to intravenous immunoglobulin were able to be accurately identified.

Researchers found that certain mutations in KLHL6 can lead to an increase in the number of B-cell receptors, resulting in poor outcomes for patients with diffuse large B-cell lymphoma.

This narrative review dispels the long-held belief that reduction in salt intake leads to better health outcomes in patients with heart failure.

As dupilumab garners positive clinical trial results in patients with chronic obstructive pulmonary disease, it is increasingly important that pharmacists educate themselves on the treatment.

The committee, after being presented evidence by the working group, recommended the vaccine for adults aged 65 and older and those 19 or older who have current recommendations to receive a pneumococcal vaccine.

In a rare case of non-tumor anti-Tr/DNER antibody-associated ataxia, the patient is treated with plasmapheresis and intravenous immunoglobulin (IVIG) for symptoms such as dysarthria and difficulty walking.

This is the first novel, precision mechanism of action to be released to treat patients with CIDP in over 3 decades.